AstraZeneca PLC Director/PDMR Shareholding (7876A)
March 28 2017 - 11:00AM
UK Regulatory
TIDMAZN
RNS Number : 7876A
AstraZeneca PLC
28 March 2017
28 March 2017 16:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announces that, on 28 March 2017,
awards of the Company's ordinary shares of $0.25 each (Ordinary
Shares) and of American Depositary Shares (ADSs) vested to certain
Persons Discharging Managerial Responsibilities of the Company
(PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the
AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent
to one Ordinary Share.
The AZDBP award was granted on 28 March 2014, following the
deferral of a portion of each PDMR's annual bonus paid in respect
of 2013 performance into Ordinary Shares or ADSs, and vested on
completion of the three-year holding period.
The AZPSP award was granted on 28 March 2014. Following the
application of performance measures specified at the time of grant,
92% of the AZPSP vested and the remaining unvested part immediately
and irrevocably lapsed.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, the PDMRs' beneficial interests in
Ordinary Shares and ADSs changed as detailed in the table
below:
PDMR Ordinary ADSs acquired Ordinary ADSs acquired
Shares under the Shares under the
acquired AZDBP acquired AZPSP
under the under the
AZDBP AZPSP
-------------- ----------- -------------- ----------- --------------
Pascal
Soriot 14,209 101,584
-------------- ----------- -------------- ----------- --------------
Marc Dunoyer 1,419 25,478
-------------- ----------- -------------- ----------- --------------
Mark Mallon 620 22,000
-------------- ----------- -------------- ----------- --------------
For tax purposes, the fair market value of an Ordinary Share at
vest was 4974.5 pence and the fair market value of an ADS at vest
was $31.80, being the relevant closing prices on the last trading
day preceding the vesting day.
Further details are set out in the attached notifications, made
in accordance with the requirements of the EU Market Abuse
Regulation.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Pascal Soriot
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
--- ------------------------- ------------------------------------
4i Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of Ordinary Shares of US$0.25
the financial each in AstraZeneca PLC
instrument, type
of instrument
GB0009895292
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the Acquisition of ordinary shares
transaction pursuant to vestings under
the AstraZeneca Deferred
Bonus Plan and the AstraZeneca
Performance Share Plan, for
nil consideration.
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
0 115,793
--------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 28 March 2017
--- ------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
--- ------------------------- ------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Marc Dunoyer
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Chief Financial Officer
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
--- ------------------------- ------------------------------------
4i Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of Ordinary Shares of US$0.25
the financial each in AstraZeneca PLC
instrument, type
of instrument
GB0009895292
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the Acquisition of ordinary shares
transaction pursuant to vestings under
the AstraZeneca Deferred
Bonus Plan and the AstraZeneca
Performance Share Plan, for
nil consideration.
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
0 26,897
--------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 28 March 2017
--- ------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
--- ------------------------- ------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Mark Mallon
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Person Discharging Managerial
Responsibilities
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
--- ------------------------- ------------------------------------
4i Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of AstraZeneca PLC American
the financial Depositary Shares
instrument, type
of instrument
CUSIP: 046353108
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the Acquisition of ADSs pursuant
transaction to vestings under the AstraZeneca
Deferred Bonus Plan and the
AstraZeneca Performance Share
Plan, for nil consideration.
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
0 22,620
--------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 28 March 2017
--- ------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
--- ------------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUWSORBNAOUAR
(END) Dow Jones Newswires
March 28, 2017 11:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
